INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Carver Kyle reported EVMN

Chief Financial Officer · Evommune, Inc. · Evommune, Inc. — Employee Stock Option (Right to Buy)

Side
A
Value
—
Shares
279.4K
Price
—
Executed
Nov 5, 2025
Disclosed
Nov 7, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 5 executedNov 7, 2025 disclosed

EVMN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · EVMN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    19
    PC
    Pena Luis C.Director, President & CEO
    EVMNEvommune, Inc.
    Grant or award
    		A$7,827
    1,115 sh
    		Sep 30, 2026Oct 15, 2026
    traded Sep 30, 2026
    		+15dSEC FORM 4

    Evidence

    3
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M$15K
    3,839 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M$5,714
    1,488 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    6
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$33K
    1,488 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    7
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M$48K
    16.2K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    24
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$453K
    20.0K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    3
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M—
    3,839 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    11
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M—
    16.2K sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,488 sh
    		Jun 22, 2026Jun 24, 2026
    traded Jun 22, 2026
    		+2dSEC FORM 4

    Evidence

    10
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M$52K
    13.5K sh
    		Jun 1, 2026Jun 3, 2026
    traded Jun 1, 2026
    		+2dSEC FORM 4

    Evidence

    11
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Option exercise · 10b5-1 plan
    		M—
    13.5K sh
    		Jun 1, 2026Jun 3, 2026
    traded Jun 1, 2026
    		+2dSEC FORM 4

    Evidence

    19
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$379K
    16.7K sh
    		Jun 1, 2026Jun 3, 2026
    traded Jun 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Drew Janice SuzannChief of Dev. Operations
    EVMNEvommune, Inc.
    Grant or award
    		A—
    73.9K sh
    		Apr 16, 2026Apr 17, 2026
    traded Apr 16, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Grant or award
    		A—
    69.3K sh
    		Apr 16, 2026Apr 17, 2026
    traded Apr 16, 2026
    		+1dSEC FORM 4

    Evidence

    18
    VI
    Verduyn-van Weegen Felice IsabelDirector, 10% Owner
    EVMNEvommune, Inc.
    Grant or award
    		A$10.00M
    358.7K sh
    		Feb 17, 2026Feb 18, 2026
    traded Feb 17, 2026
    		+1dSEC FORM 4

    Evidence

    19
    BE
    Bauer EugeneDirector, Chief Medical Officer
    EVMNEvommune, Inc.
    Grant or award
    		A—
    100.0K sh
    		Dec 8, 2025Dec 19, 2025
    traded Dec 8, 2025
    		+11dSEC FORM 4

    Evidence

    16
    PP
    Patel Jeegar PravinkumarChief Scientific Officer
    EVMNEvommune, Inc.
    Tax withholding
    		F$134K
    7,513 sh
    		Dec 9, 2025Dec 11, 2025
    traded Dec 9, 2025
    		+2dSEC FORM 4

    Evidence

    16
    DS
    Drew Janice SuzannEVP, Operations
    EVMNEvommune, Inc.
    Tax withholding
    		F$91K
    5,074 sh
    		Dec 9, 2025Dec 11, 2025
    traded Dec 9, 2025
    		+2dSEC FORM 4

    Evidence

    20
    CK
    Carver KyleChief Financial Officer
    EVMNEvommune, Inc.
    Tax withholding
    		F$237K
    13.3K sh
    		Dec 9, 2025Dec 11, 2025
    traded Dec 9, 2025
    		+2dSEC FORM 4

    Evidence

    20
    MS
    Moss Gregory S.Chief Business & Legal Officer
    EVMNEvommune, Inc.
    Tax withholding
    		F$243K
    13.6K sh
    		Dec 9, 2025Dec 11, 2025
    traded Dec 9, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001757072-25-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 5, 2025
    Published
    Nov 7, 2025
    Ingested by INSIDER
    Nov 5, 04:34 UTC
    Last re-read
    Nov 5, 04:34 UTC

    Extracted facts

    Filer
    Carver Kyle
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Evommune, Inc. — Employee Stock Option (Right to Buy)
    Ticker
    EVMN
    Shares
    279.4K
    Price per share
    $0
    Execution date (reported)
    Nov 5, 2025
    Owned after transaction
    279.4K shares
    Days from execution to publication
    2

    What this establishes

    Carver Kyle filed this Form 4 reporting a grant or award of EVMN on Nov 5, 2025. It became public on Nov 7, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Carver Kylecik:0001757072
    Issuer
    Evommune, Inc.cik:0002044725

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.